Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of 9-valent HPV Vaccine (Hansenula Polymorpha) in Chinese Women
NCT04422366Phase 3Recruiting
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Sep 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine (Hansenula polymorpha) in Cervical Cancer (CC), vulvar cancer, vaginal cancer, anal cancer, genital warts, sponsored by Shanghai Bovax Biotechnology Co., Ltd.. Started Apr 2020; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine (Hansenula polymorpha)
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal canceranal cancergenital warts
Beyond the preview
Go deeper on NCT04422366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422366.